Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misleading investors regarding its accounts receivable and financial reporting [1][2]. Group 1: Allegations - The complaint states that Ardent Health reported inflated accounts receivable and delayed recognizing losses on uncollectable accounts [2]. - It is alleged that Ardent Health did not maintain sufficient professional malpractice liability insurance to cover claims arising from its operations [2]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, leading to a significant stock price drop of nearly 34% [2]. Group 2: Legal Actions - Shareholders who purchased Ardent Health securities between July 18, 2025, and November 12, 2025, may be eligible to participate in the class action [1][3]. - Interested shareholders must submit their papers to the court by March 9, 2026, to serve as lead plaintiff [3]. Group 3: Company Background - Ardent Health, Inc. operates acute care hospitals and other healthcare facilities [1].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ardent Health (ARDT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ardent Health securities between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- What’s Ha ...

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines following revelations of financial discrepancies [3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable, which inflated reported financial positions [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable assessments, resulting in a nearly 34% drop in stock price [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. Group 2: Legal Process and Representation - Investors who purchased Ardent Health securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [5]. Group 3: Company Overview - Ardent Health operates a network of hospitals and clinics providing various healthcare services [2].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed by Bleichmar Fonti & Auld LLP on behalf of investors in Ardent Health securities, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Middle District of Tennessee [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - Ardent Health is accused of misrepresenting its process for determining the collectability of accounts receivable, claiming to rely on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allegedly allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million decrease in revenue for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - Ardent Health, Inc. is facing a federal securities class action lawsuit due to allegations of misleading investors regarding its accounts receivable collectability practices, with a deadline for lead plaintiff applications set for March 9, 2026 [1][3]. Group 1: Lawsuit Details - The lawsuit pertains to investors who acquired Ardent securities between July 18, 2024, and November 12, 2025, during which the company allegedly misrepresented its monitoring process for accounts receivable [3]. - Ardent claimed to use detailed reviews of historical collections to assess collectability, but it actually relied on a 180-day cliff method, which allowed for inflated accounts receivable reporting and delayed loss recognition [3]. Group 2: Financial Impact - On November 12, 2025, Ardent disclosed a $43 million revenue reduction due to changes in accounting estimates for accounts receivable collectability and a $54 million increase in professional liability reserves related to New Mexico claims [4]. - Following this announcement, Ardent's share price fell by $4.75, or approximately 33.8%, from $14.05 to $9.30 per share [4].

LOS ANGELES, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming March 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ARDENT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS T ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardent To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ardent between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 30, 2026 /PRNewswire/ -- Faruqi & Faruqi, ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].